EASE LID 3

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

Thématique(s) / pathologie(s)

  • Maladie de Parkinson

Objectifs

Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/NCT02274766?term=Adamas&cond=parkinson&cntry=FR&draw=2&rank=1

Promoteur

Adamas Pharmaceuticals, Inc.

Publication(s) scientifique(s)

  • Oertel W et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord. 2017 Dec;32(12):1701-1709. 

    https://pubmed.ncbi.nlm.nih.gov/28833562/

Statut

Résultats publiés

Centres participants

Partager

Mis à jour le 25 janvier 2023